Table 3.
Clinical characteristics of the study subjects with telbivudine therapy for the longitudinal study.
| Group | CR | NCR | P value | |
|---|---|---|---|---|
| No. of patients (M/F) | 3 (1/2) | 2 (2/0) | 0.136 a | |
| Age (year) | 34.00 (24.00-35.00) | 25.50 (25.00-26.00) | 0.800 b | |
| 0 weeks | HBV DNA (lg copies/mL) | 8.63 (8.38-8.88) | 8.18 (8.04-8.32) | 0.800 b |
| ALT (U/L) | 253.00 (159.00-256.00) | 258.00 (222.00-294.00) | 0.983 b | |
| eAg (P/N) | 3/0 | 2/0 | ||
| 48 weeks | HBV DNA (lg copies/mL) | n.d. | n.d. | |
| ALT (U/L) | 14.00 (10.00-18.00) | 19.00 (15.00-23.00) | 0.400 b | |
| eAg (P/N) | 0/3 | 2/0 | 0.025 a |
Data were shown as median (25-75% percentile).
a
Chi-squared test.
b
Mann-Whitney U test.
ALT, alanine aminotransferase; CR, complete response; eAg, hepatitis B e antigen; NCR, non-complete response; P/N, positive or negative.